Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Robert Orlowski is the Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, USA. His research focuses on multiple myeloma, hematologic malignancies, and the tumor immune microenvironment, as evidenced by his recent publications. He has contributed significantly to studies exploring the treatment of relapsed and refractory conditions, outcomes in stem cell transplantation, and the advancements in clinical protocols for multiple myeloma.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Ken Furudate

The University of Texas MD Anderson Cancer Center

UNITED STATES

Robert Orlowski

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states

Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)

Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant.

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.

Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Outcomes of multiple myeloma patients with prior solid tumors undergoing autologous transplantation

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.

Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades

Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from <scp>GRIFFIN</scp>

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.

Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience

Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.

Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.

Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.

Collaborators (15)

Ken Furudate

Karthik Ramasamy

Pawel Robak

Brandi N. Reeves

Peter Kuhn

Argiris Symeonidis

Oren Pasvolsky

Qaiser Bashir

Saad Usmani

Yago Nieto

Paul Lin

Larry Anderson

Joaquin Martinez-Lopez

Michael E. O'Dwyer

Jeremy Ramdial

Make your next move.